Title
The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood
Author
Lopatinskaya, L.
Boxel van-Dezaire, A.H.H.
Barkhof, F.
Polman, C.H.
Lucas, C.J.
Nagelkerken, L.
Publication year
2003
Abstract
In this longitudinal study, we examined the expression of Fas, FasL, CCR3, CCR5 and CXCR3 mRNA in peripheral blood mononuclear cells (PBMCs) of secondary progressive (SP) and relapsing-remitting (RR) multiple sclerosis (MS) patients. In RR patients, FasL, CCR3 and CCR5 mRNA levels were increased prior to the exacerbations, but these decreased during clinical activity, while mRNA levels of Fas increased. SP patients have increased the levels of Fas and FasL mRNA; the latter was particularly increased during lesional activity. Our data support the hypothesis that changes in Fas and FasL mRNA related to clinical activity are due to the migration of inflammatory cells to the central nervous system (CNS). © 2003 Elsevier Science B.V. All rights reserved. Chemicals/CAS: Antigens, CD95; CC chemokine receptor 3; CXC chemokine receptor 3; Fas Ligand Protein; FASLG protein, human; Ligands; Membrane Glycoproteins; Receptors, CCR5; Receptors, Chemokine; RNA, Messenger
Subject
Health
CCR3
CCR5
CXCR3
Fas (Apo-1, CD95)
Fas Ligand (CD95L, CD178)
Chemokine receptor CCR3
Chemokine receptor CCR5
Chemokine receptor CXCR3
Fas antigen
FAS ligand
Messenger RNA
Blood
Cell migration
Central nervous system
Clinical article
Controlled study
Disease activity
Disease exacerbation
Inflammatory cell
Mononuclear cell
Multiple sclerosis
Protein expression
Adult
Antigens, CD95
Apoptosis
Cross-Sectional Studies
Down-Regulation
Fas Ligand Protein
Humans
Ligands
Longitudinal Studies
Membrane Glycoproteins
Middle Aged
Multiple Sclerosis, Chronic Progressive
Multiple Sclerosis, Relapsing-Remitting
Receptors, CCR5
Receptors, Chemokine
RNA, Messenger
Up-Regulation
To reference this document use:
http://resolver.tudelft.nl/uuid:a7dc66b4-c46d-4c5b-b819-0f6cd082552d
DOI
https://doi.org/10.1016/s0165-5728(03)00089-4
TNO identifier
237074
ISSN
0165-5728
Source
Journal of Neuroimmunology, 138 (1-2), 123-131
Document type
article